Earnings results for Alpine Immune Sciences (NASDAQ:ALPN)
Alpine Immune Sciences, Inc. is expected* to report earnings on 11/12/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.23. The reported EPS for the same quarter last year was $-0.62.
Alpine Immune Sciences last issued its quarterly earnings data on August 11th, 2020. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.30. The firm earned $0.69 million during the quarter, compared to the consensus estimate of $2.13 million. Alpine Immune Sciences has generated ($2.28) earnings per share over the last year. Alpine Immune Sciences has confirmed that its next quarterly earnings report will be published on Thursday, November 12th, 2020.
Analyst Opinion on Alpine Immune Sciences (NASDAQ:ALPN)
6 Wall Street analysts have issued ratings and price targets for Alpine Immune Sciences in the last 12 months. Their average twelve-month price target is $16.80, predicting that the stock has a possible upside of 110.00%. The high price target for ALPN is $22.00 and the low price target for ALPN is $8.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Alpine Immune Sciences has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $16.80, Alpine Immune Sciences has a forecasted upside of 110.0% from its current price of $8.00. Alpine Immune Sciences has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Alpine Immune Sciences (NASDAQ:ALPN)
Alpine Immune Sciences does not currently pay a dividend. Alpine Immune Sciences does not have a long track record of dividend growth.
Insiders buying/selling: Alpine Immune Sciences (NASDAQ:ALPN)
In the past three months, Alpine Immune Sciences insiders have not sold or bought any company stock. 76.10% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health. Only 29.95% of the stock of Alpine Immune Sciences is held by institutions.
Earnings and Valuation of Alpine Immune Sciences (NASDAQ:ALPN
Earnings for Alpine Immune Sciences are expected to grow in the coming year, from ($1.29) to ($0.62) per share. The P/E ratio of Alpine Immune Sciences is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Alpine Immune Sciences is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Alpine Immune Sciences has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here